Background: Diabetes has been associated with an increased risk of peripheral arterial disease (PAD) and worse outcomes following treatment. The DEFINITIVE LE study was a global study that assessed the effectiveness of plaque excision using the SilverHawk® and TurboHawkTM systems (Covidien/ev3, Plymouth, MN) for endovascular treatment of PAD in femoropopliteal and tibial-peroneal arteries. Methods: 800 patients with a total of 1023 infrainguinal lesions were enrolled in DEFINITIVE LE and underwent revascularization with plaque excision. Follow-up assessments occurred at pre-discharge, 30 days, 3 months (for patients with RCC 5 or 6), 6 months and 1 year post-procedure. Endpoints were assessed by independent angiographic and duplex core laboratories and adverse events were adjudicated by a Clinical Events Committee. The primary endpoint for claudicants was primary patency (defined using both PSVR Յ 2.4 and PSVR Յ 3.5and estimated by Kaplan-Meier methods). Secondary assessments included change in Rutherford Clinical Category, ankle-brachial index, the Walking Impact Questionnaire, EQ-5D quality of life and adverse events. Results: Preliminary results are shown pending database closure and monitoring; final results will be presented at TCT 2012. The study enrolled 600 subjects (745 lesions) with claudication, 46.7% (280/600) of which had diabetes. Subjects with diabetes differed significantly from those without diabetes in multiple baseline characteristics, but acute and 1-year outcomes were largely similar. Demographics, lesion characteristics and outcomes are shown below.

